ArticleCancer research2020
Penetrance of Different Cancer Types in Families with Li-Fraumeni Syndrome: A Validation Study Using Multicenter Cohorts.
Open access · greenAbstract readComment
In one paragraph
Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- Performance of LFSPRO prediction in TP53 mutation status for prospectively collected probands.American journal of human genetics · 2026Article
- A Novel Approach to Prognostic Factors and Risk Stratification in Pediatric AML: Case Report and Literature Review.International journal of molecular sciences · 2025Review
- Characterization of p53 p.T253I as a pathogenic mutation underlying Li-Fraumeni Syndrome.PloS one · 2025Article
- TheBioinformatics advances · 2025Article
- Current insights and future directions of Li-Fraumeni syndrome.Discover oncology · 2024Review
- Article
- Validating Risk Prediction Models for Multiple Primaries and Competing Cancer Outcomes in Families With Li-Fraumeni Syndrome Using Clinically Ascertained Data.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- LFSPROShiny: An Interactive R/Shiny App for Prediction and Visualization of Cancer Risks in Families With Deleterious GermlineJCO clinical cancer informatics · 2024Article
- Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome.International journal of molecular sciences · 2024Review
- LFSPROShiny: an interactive R/Shiny app for prediction and visualization of cancer risks in families with deleterious germlinemedRxiv : the preprint server for health sciences · 2023Article
- A Novel Variant in theChildren (Basel, Switzerland) · 2023Article
- Hereditary cancer syndromes.World journal of clinical oncology · 2023Review
- Patient decision support resources inform decisions about cancer susceptibility genetic testing and risk management: a systematic review of patient impact and experience.Frontiers in health services · 2023Review
- Family communication challenges of adolescents and young adults with Li-Fraumeni syndrome: Implications for psychosocial care.Patient education and counseling · 2022Article
- Segregation analysis of 17,425 population-based breast cancer families: Evidence for genetic susceptibility and risk prediction.American journal of human genetics · 2022Article
- Li-Fraumeni Syndrome: Mutation ofCancers · 2022Review
- Inherited TP53 Variants and Risk of Prostate Cancer.European urology · 2022Article
- Breast cancer characteristics and surgery among women with Li-Fraumeni syndrome in Germany-A retrospective cohort study.Cancer medicine · 2021Article
- Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants.Human mutation · 2021Article
- New surveillance guidelines for Li-Fraumeni and hereditary TP53 related cancer syndrome: implications for germline TP53 testing in breast cancer.Familial cancer · 2021Article
Corrections and comments
- Comment on
Authors and funding
15 authors at 6 institutions in 4 countries.
Seung Jun ShinDepartment of Statistics, Korea University, Seoul, South Korea.
Elissa B Dodd-EatonDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Gang PengDepartment of Biostatistics, Yale University, New Haven, Connecticut.
Jasmina BojadzievaDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jingxiao ChenDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-2461-4616
Christopher I AmosDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-8540-7023
Megan N FroneClinical Genetics Branch, Division of Cancer Genetic and Epidemiology, NCI, Bethesda, Maryland.
Payal P KhinchaClinical Genetics Branch, Division of Cancer Genetic and Epidemiology, NCI, Bethesda, Maryland.
Phuong L MaiCancer Genetics Program, Magee Womens Hospital, Pittsburgh, Pennsylvania.
Sharon A SavageClinical Genetics Branch, Division of Cancer Genetic and Epidemiology, NCI, Bethesda, Maryland.ORCID 0000-0001-6006-0740
Mandy L BallingerThe Kinghorn Cancer Center and Garvan Institute of Medical Research, Darlinghurst, Australia.
David M ThomasThe Kinghorn Cancer Center and Garvan Institute of Medical Research, Darlinghurst, Australia.
Ying YuanDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Louise C StrongDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-6795-3744
Wenyi WangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas. wwang7@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USCancer Genetics (United States) · USGarvan Institute of Medical Research · AUChildren's Cancer Center · USMagee-Womens Hospital · USYale University · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MYale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI MEGAN C KING · 1985 to 2026
$85.0MYale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung CancerP50CA196530 · NCI · YALE UNIVERSITY · PI Kurt A Schalper · 2015 to 2026
$31.1MTRANSCRIPTIONAL REGULATION OF WT-1P01CA034936 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUFF, VICKI · 1985 to 2010
$26.4MTranslating Molecular and Clinical Data to Population Lung Cancer Risk AssessmentU19CA203654 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Christopher I. Amos · 2017 to 2026
$23.7MCoordinating Center: Molecular and Cellular Findings of Screen-Detected LesionsU01CA196386 · NCI · DARTMOUTH COLLEGE · PI AMOS, CHRISTOPHER I. · 2015 to 2020
$4.1MGenome-Wide Association Study (GWAS) in Hepatocellular Carcinoma (HCC)R01CA186566 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AMOS, CHRISTOPHER I., HASSAN, MANAL METWALLY · 2015 to 2019
$3.6MConsistent variable selection in p>>n settingsR01CA158113 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI JOHNSON, VALEN EARL · 2011 to 2020
$2.8MStatistical methods for genomic analysis of heterogeneous tumorsR01CA183793 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WANG, WENYI · 2014 to 2018
$1.7MBioinformatics Tools for Genomic Analysis of Tumor and Stromal Pathways in CancerR01CA174206 · NCI · DANA-FARBER CANCER INST · PI PARMIGIANI, GIOVANNI LUIGI · 2013 to 2017
$1.7MStatistical methods and tools for cancer risk prediction in families with germline mutations in TP53R01CA239342 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WANG, WENYI · 2019 to 2022
$1.5MNCI NIH HHS P01 CA034936NCI NIH HHS P30 CA016359NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA196530NCI NIH HHS R01 CA158113NCI NIH HHS R01 CA174206NCI NIH HHS R01 CA183793NCI NIH HHS R01 CA186566NCI NIH HHS R01 CA239342NCI NIH HHS U01 CA196386NCI NIH HHS U19 CA203654
Abstract
Li-Fraumeni syndrome (LFS) is a rare hereditary cancer syndrome associated with an autosomal-dominant mutation inheritance in the
Indexed as
Li-Fraumeni SyndromeNeoplasms, Second PrimaryChildGenetic Predisposition to DiseaseGerm-Line MutationHumansPedigreePenetranceTumor Suppressor Protein p53Tumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.